A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines

Table 5 Summary of back-transformed LS means PCV2 copies/5 µL in serum (viremia) by treatment group and study day for studies B and C (evaluation of monovalent vs bivalent vaccines)

Study	Treatment Group (T)	Day of study								% pigs ever positive post challenge
Study	Treatment Group (T)	− 1	21	24	28 or 29	31	35	38	42	% pigs ever positive post challenge
B	T01	0	0	0	5.69E + 03	1.72E + 04	1.84E + 04	1.38E + 04	1.44E + 04	100
B	T02	0	0	0	0.6*	2.0*	4.4*	5.9*	2.9*	36.4*
B	T03	0	0	0	1.4*	1.4*	0.5*	0.7*	0.5*	26.1*
C	T01	0	0	0	7.34E + 02	1.76E + 04	9.68E + 02	1.22E + 04	2.33E + 02	100
C	T02	0	0	0	13.5**	21.8**	1.8**	5.6**	0.8**	52.4**
C	T03	0	0	0.6	4.5**	1.4**	0.6**	5.7**	0.5**	40.9**

Value is significantly different from T01 saline controls (*P < 0.0001, **P ≤ 0.05) within a column (day of study; study day 0 corresponded to the day of vaccination).

ISSN: 1297-9716